Melanotan II vs Bremelanotide

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicMelanotan IIBremelanotide
What it is

A synthetic cyclic peptide, N-acetyl-norleucyl-aspartyl-histidyl-D-phenylalanyl-arginyl-tryptophyl-lysinamide closed into a ring between its second and seventh units, according to FDA’s substance registry.4

A melanocortin receptor agonist. The label states that it activates several receptor subtypes, of which MC1R and MC4R are most relevant.2

FDA status

Not FDA-approved

No FDA approval reported; on FDA’s compounding safety-risk list1

No FDA approval is reported in the sources reviewed here. FDA lists Melanotan II among bulk substances whose compounding nominations were withdrawn and that may present significant safety risks.1

Is Melanotan II FDA-approved?

FDA-approved

FDA-approved as Vyleesi for HSDD in premenopausal women2,3

FDA-approved. Drugs@FDA lists Vyleesi with an original approval date of June 21, 2019, for HSDD in premenopausal women. The cited label has no boxed warning.2,3

Is bremelanotide FDA-approved?

HHS compounding policy, October 30, 2026

Not among the six peptides the policy lists.5

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Melanotan II is not among them.5,6

Not among the six peptides the policy lists.5

FDA compounding safety-risk page

Listed.

FDA’s compounding safety-risk page, current as of April 22, 2026, lists Melanotan II among bulk substances previously in category 2 whose nominations were withdrawn, citing possible immune reactions from aggregation or impurities and the case reports above.1

Not addressed in this profile’s sources.

Kinds of studies cited

Smaller controlled human trials

  • Controlled human trial A double-blind, placebo-controlled crossover study in 10 men with erectile dysfunction and organic risk factors, published in 2000.7
  • Small, short, or incompletely reported human study A 1996 single-blind, placebo-controlled pilot study in three healthy men over two weeks.8
  • Small, short, or incompletely reported human study Published case reports, cited by FDA, of serious adverse events in people who used Melanotan II, including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism.1

Large randomized human trials

  • Large randomized human trial Two identical randomized, double-blind, placebo-controlled Phase 3 trials (NCT02333071 and NCT02338960) that together randomized 1,267 participants, all premenopausal women with acquired, generalized HSDD, with a 24-week placebo-controlled phase.2
Records collected

0 ClinicalTrials.gov records and 16 PubMed records collected

6 ClinicalTrials.gov records and 21 PubMed records collected

Area of study

Skin1

Sexual and reproductive health2

Latest dated events
  1. FDA’s compounding safety-risk page, as last updated, lists Melanotan II among withdrawn nominations with safety concerns.1
  2. FDA’s advisory committee page lists Melanotan II for discussion at a meeting before the end of February 2027.9
  3. Results of a placebo-controlled crossover study of Melanotan II in 10 men with erectile dysfunction are published.7
  1. FDA approves a Vyleesi labeling supplement that updates the label’s section on use in specific populations.10
  2. DailyMed publishes the Vyleesi label version cited on this page.2
  3. FDA approves Vyleesi, according to Drugs@FDA.3

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  2. 2
    VYLEESI (bremelanotide) injection · SPL version 1 · published 2025-11-18 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

  3. 3
    Drugs@FDA application NDA210557 · original submission status AP · 2019-06-21 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  4. 4
    Melanotan II substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  5. 5
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  6. 6
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  7. 7
    Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction (2000) · PMID 11018622 ↗

    Urology · Official source · Source checked November 16, 2026

  8. 8
    Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study (1996) · PMID 8637402 ↗

    Life Sciences · Official source · Source checked November 16, 2026

  9. 9
    Meeting of the Pharmacy Compounding Advisory Committee (before the end of February 2027) · content current as of April 15, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026

  10. 10
    Vyleesi (bremelanotide): NDA 210557 supplement S-005 approval letter, October 22, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026